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Abstract
Background—Recommended colorectal cancer (CRC) screening tests for adults ages 50 to 75 
years include home fecal occult blood tests (FOBT), sigmoidoscopy with FOBT, and colonoscopy. 
A newer test, computed tomographic (CT) colonography, has been recommended by some, but not 
all, national organizations.
Methods—We analyzed 2010 National Health Interview Survey data, including new CT 
colonography questions, from respondents ages 50 to 75 years (N =8,952). We (i) assessed 
prevalence of CRC test use overall, by test type, and by sociodemographic and health care access 
factors and (ii) assessed reported reasons for not having a CRC test.
Results—The age-standardized percentage of respondents reporting FOBT, sigmoidoscopy, or 
colonoscopy within recommended time intervals was 58.3% [95% confidence interval (CI), 57.0–
59.6]. Colonoscopy was the most commonly reported test [within past 10 years: 54.6% (95% CI, 
53.2–55.9)]. Home FOBT and sigmoidoscopy with FOBT were less frequently used [FOBT within 
past year: 8.8% (95% CI, 8.1–9.6); sigmoidoscopy within past 5 years with FOBT within past 3 
years: 1.3% (95% CI, 1.0–1.6)]. CT colonography was rare: 1.3% (95% CI, 1.0–1.7). Increasing 
age, education, income, having health care insurance, and having a usual source of health care 
were associated with higher CRC test use. Test use within recommended time intervals was 
particularly low among individuals ages 50 to 64 years without health care insurance [21.2% (95% 
CI, 18.3–24.4)]. The most common reason for nonuse was “no reason or never thought about it.”
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Conclusions—About 40% of Americans ages 50 to 75 years do not meet the recommendations 
for having CRC screening tests.
Impact—Expanded health care coverage and greater awareness of CRC screening are needed to 
further decrease CRC mortality.
Introduction
A variety of tests are available for colorectal cancer (CRC) screening. The U.S. Preventive 
Services Task Force (USPSTF) recommends that adults ages 50 to 75 years be screened 
with fecal occult blood testing (FOBT) every year, or sigmoidoscopy every 5 years with 
FOBT every 3 years, or colonoscopy every 10 years (1). Evidence clearly indicates that 
screening with any of these 3 tests reduces CRC mortality in this age group (2–7). For adults 
ages 76 to 85 years, routine CRC screening is not recommended by the USPSTF, although 
CRC screening in an individual patient in this age group may be appropriate if the patient 
has not been previously screened and is reasonably healthy (1). For adults older than 85 
years, the USPSTF recommends against CRC screening (1). Recommendations from other 
organizations have not specified an age to stop CRC screening (8).
A newer test that can be used for CRC screening is computed tomographic (CT) 
colonography, also called virtual colonoscopy. CT colonography is an X-ray test, which uses 
CT scanning and computer software to generate 2- and 3-dimensional images of the colon 
and rectum, simulating a colonoscopy. In its most recent update, the USPSTF concluded that 
there is insufficient evidence to recommend CT colonography for CRC screening (1). 
However, other organizations have recommended CT colonography every 5 years as a CRC 
screening option (8). In the National CT Colonography Trial of the American College of 
Radiology Imaging Network (ACRIN), CT colonography identified 90% of subjects with 
large adenomas or cancers on colonoscopy but had a lower sensitivity for smaller CRC 
lesions (9). A recent study in the Netherlands found that participation was higher for CT 
colonography than for colonoscopy and found a similar diagnostic yield for advanced 
neoplasia for both strategies (10).
The prevalence of use of the different types of CRC screening tests has changed over time 
(11, 12). To assess the current prevalence of use of CRC screening tests overall and by 
specific test types, we analyzed data from the 2010 National Health Interview Survey 
(NHIS) on use of home FOBT, sigmoidoscopy, colonoscopy, and CT colonography for the 
U.S. adult population. We also examined use of the different types of CRC tests by 
sociodemographic and health care access factors. For those respondents who had never had 
or were not up-to-date with CRC testing, we assessed the reported reasons they did not have 
a CRC test.
Materials and Methods
Study population
The NHIS is an in-person survey of the civilian, non-institutionalized U.S. population, 
conducted by the National Center for Health Statistics (NCHS) of the Centers for Disease 
Control and Prevention (CDC; ref. 13). A representative sample of households is selected by 
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a multistage cluster sample design. U.S. Census Bureau interviewers visit each selected 
household to administer the survey. CDC’s Division of Cancer Prevention and Control and 
the National Cancer Institute’s Division of Cancer Control and Population Sciences sponsor 
the Cancer Control Supplement to the NHIS. The Cancer Control Supplement and Sample 
Adult Core obtain information from a randomly selected adult in each family of related 
household members. The 2010 Sample Adult conditional response rate, which is only for 
those adults identified as eligible and does not take into account family nonresponse, was 
77.3% (13). The unconditional Sample Adult response rate was 60.8%, calculated by 
multiplying the conditional rate by the family response rate.
Some respondents did not complete the survey and were not asked any of the CRC 
questions. These respondents were excluded from all analyses (N = 725 for ages 50–75 years 
and N = 127 for ages 76–84 years). Respondents with a personal history of CRC or missing 
information on history of CRC were also excluded from all analyses (N =105 for ages 50–75 
years and N =46 for ages 76–84 years). For most of our analyses, only respondents ages 50 
to 75 years were included (N = 8,952). We conducted a subanalysis among respondents ages 
76 to 84 years (N = 1,442).
CRC test use
Respondents were asked separate questions about the use of sigmoidoscopy, colonoscopy, 
the blood stool or occult blood test, and, for the first time in the NHIS, CT colonography or 
virtual colonoscopy. Descriptions of each test were provided so that the respondents could 
identify the tests even if they did not know the name of the test (13). Separate questions 
were asked about home FOBT, described as a blood stool test using a home test kit, and 
office FOBT, described as a blood stool test in which a doctor or other health care 
professional collects a stool sample during an office visit. In our primary analysis, we only 
include information on use of home FOBT, not office FOBT, because national guidelines 
recommend use of home FOBT (1, 8). We analyzed use of CT colonography separately 
because it is not recommended for CRC screening by the USPSTF (1). Use of any CRC test 
within the recommended time interval was defined as use of home FOBT within the past 
year, use of sigmoidoscopy within the past 5 years in combination with home FOBT within 
the past 3 years, or use of colonoscopy within the past 10 years.
For each type of CRC test, respondents were asked when they had their most recent test. 
Respondents who had not had a colonoscopy in the past 10 years, a sigmoidoscopy in the 
past 5 years, a CT colonography in the past 5 years, or an FOBT in the past year were also 
asked the most important reason why they did not have any kind of test to look for problems 
in their colon or rectum.
While the NHIS asks about test indication, CRC tests conducted for any indication were 
included in the analysis because the reported indication for a CRC test may not always be 
accurate (14), and even if a test was conducted for nonscreening purposes, a person would 
have been considered effectively screened.
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Correlates
Table 1 lists the self-reported variables that were examined in relation to CRC test use. 
Respondents who reported they were of multiple races but also reported a primary race were 
included in the primary race category. Missing data for race and ethnicity were imputed by 
hot-deck imputation (13). Missing income data were imputed using multiple imputation 
(15).
Respondents were asked whether there was a place where they usually go when they are sick 
or need advice about their health. Respondents reporting the hospital emergency room as 
their only usual source of health care were included among those categorized as having no 
usual source of health care, whereas those respondents who reported other places were 
classified as having a usual source of health care.
For Table 1, the health care insurance variable was grouped into different categories 
depending on age. For ages 50 to 64 years, the health care insurance categories were (i) any 
private insurance, with or without other coverage; (ii) military health coverage without 
private insurance, but including those with other government/public coverage; (iii) only 
government/public coverage other than military (without private insurance; includes 
Medicare, Medicaid, state-sponsored health plan, Indian Health Service, Children’s Health 
Insurance Program); and (iv) no coverage or single service plans only. Single service plans 
only pay for one type of service such as dental care, vision care, or prescriptions. For ages 
65 to 75 years, the health care insurance categories were (i) private insurance, with or 
without Medicare or other coverage; (ii) Medicare coverage without private insurance, 
including those with Medicare plus other public coverage; (iii) only government/public 
coverage other than Medicare (includes military, Medicaid, state-sponsored health plan, 
Indian Health Service, Children’s Health Insurance Program); and (iv) no coverage or single 
service plan only.
Statistical analysis
To provide national estimates of the prevalence of CRC test use, responses were weighted to 
reflect the probability of selection with adjustments for nonresponse and poststratification. 
Percentages with 95% confidence intervals (CI) based on a logit transformation were 
calculated using SAS version 9.2 (SAS Institute Inc.) and SUDAAN version 10.0.1 
(Research Triangle Institute) to account for the complex survey design.
Adjusted percentages (predictive margins) in Table 2 were computed from multivariate 
logistic regression models controlling for all variables in Table 2 (16). Predictive margins 
are a type of direct standardization that averages the predicted values from the logistic 
regression models over the covariate distribution in the study population (16). The predictive 
margin for a specific group represents the average predicted response if everyone in the 
sample had been in that group. The P values in Table 2 are based on overall Wald F tests for 
association from multivariate logistic regression models. The family history of CRC variable 
was excluded from the predictive margins model due to the large amount of missing data 
(4.7%).
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Percentages in Tables 1 and 3 were age-standardized to the 2000 U.S. standard population 
using the direct method (17).
Results
A total of 67.7% (95% CI, 66.4–68.9) of respondents ages 50 to 75 years had ever had a 
home FOBT, sigmoidoscopy, or colonoscopy. The age-standardized percentage that had 
ever had each type of test was highest for colonoscopy [57.8% (95% CI, 56.5–59.1)], 
followed by home FOBT [32.9% (95% CI, 31.7–34.2)] and sigmoidoscopy [12.5% (95% CI, 
11.7–13.4)].
Table 1 shows the age-standardized percentages of respondents ages 50–75 years that 
reported CRC tests within recommended time intervals, by sociodemographic and health 
care access variables. A total of 58.3% (95% CI, 57.0–59.6) of respondents reported use of 
any CRC test within the recommended time interval (home FOBT within the past year, 
sigmoidoscopy within the past 5 years with home FOBT within the past 3 years, or 
colonoscopy within the past 10 years). Colonoscopy within the past 10 years was the most 
commonly reported test, with 54.6% (95% CI, 53.2–55.9) of respondents reporting use of 
this test. Home FOBT and sigmoidoscopy were less frequently used [home FOBT within the 
past year: 8.8% (95% CI, 8.1–9.6); sigmoidoscopy within the past 5 years with FOBT within 
the past 3 years: 1.3% (95% CI, 1.0–1.6)]. Office FOBT, which is not recommended for 
CRC screening, was used by 5.3% (95% CI, 4.7–5.9) within the past year (data not shown). 
A total of 4.3% (95% CI, 3.8–4.9) had office FOBT but did not also have home FOBT 
within the past year.
The age-standardized percentage of respondents who reported CRC testing within the 
recommended time interval was highest (>70%) for respondents with high family incomes 
(>$100,000 annually) or with a family history of CRC, and for respondents ages 50 to 64 
years with military health care insurance or ages 65 to 75 years with private health care 
insurance (Table 1). Use of CRC tests was particularly low among those lacking a usual 
source of health care [22.4%, (95% CI, 18.1–27.3)] or lacking health care insurance 
coverage [21.2% (95% CI, 18.3–24.4) for ages 50–64 years and 14.2% (95% CI, 6.6–27.7) 
for ages 65–75 years].
The largest differences in the age-standardized percentages of those reporting CRC testing 
were between subgroups defined by income, education, type of health care insurance, and 
having a usual source of health care (Table 1). Respondents with higher incomes, higher 
levels of education, or with a usual source of health care were more likely to report having a 
CRC test than were respondents with lower incomes, lower levels of education, or without a 
usual source of health care. Use of CRC tests also varied by type of health care insurance. 
For ages 50 to 64 years, respondents with military or private health care insurance were 
much more likely to have had CRC tests than respondents with no health care insurance or 
with government/public health care coverage. For ages 65 to 75 years, respondents with 
private health care insurance and/or Medicare were much more likely to have had CRC tests 
than were the few respondents with no health care insurance or with only government/public 
health care coverage.
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In the age-adjusted analyses, there were moderate differences in the percentages reporting 
CRC testing between subgroups defined by race, ethnicity, and family history of CRC 
(Table 1). Asians and Hispanics were less likely to have had CRC tests than were whites, 
blacks, or non-Hispanics. Respondents with a family history of CRC were more likely to 
have had CRC tests than respondents who did not have a family history.
In Table 2, we present the multivariate-adjusted percentages of respondents who reported 
CRC tests within recommended time intervals. For use of any CRC test within the 
recommended time interval in the multivariate models, there were statistically significant 
differences (P < 0.05) in use by race, age, education, income, type of health care insurance, 
and usual source of health care. After multivariate adjustment, the associations with 
education and income were attenuated as compared with the age-adjusted results. However, 
the associations with type of health care insurance and having a usual source of health care 
remained strong. The association with Hispanic or Latino ethnicity was eliminated after 
multivariate adjustment.
For all of the sociodemographic and health care access variables that we examined, 
colonoscopy was used much more frequently within the recommended time period than the 
other types of CRC tests. The associations of sociodemographic and health care access 
variables with colonoscopy use were similar to the associations with use of any CRC test 
(Table 2). Colonoscopy use was statistically significantly associated with race, age, 
education, income, health care insurance, and usual source of health care, after multivariate 
adjustment. FOBT use was statistically significantly associated with education, health care 
insurance, and usual source of health care. Use of FOBT was highest among respondents 
with military health care insurance (for ages 50–64 years, multivariate-adjusted: 17.5%; 
95% CI, 12.4–24.2). Patterns of association of certain factors with FOBT use and 
sigmoidoscopy use were unclear due to infrequent use of these tests.
In age-standardized estimates, 20.3% (95% CI, 19.2–21.4) of respondents had heard of CT 
colonography (Table 3). The age-standardized percentage of respondents who reported that 
they had heard of CT colonography was highest for college graduates (31.0%). Whites and 
non-Hispanics were more likely than other races or Hispanics to have heard of CT 
colonography. Respondents with private health care insurance or a usual source of health 
care were more likely to have heard of CT colonography than were those without private 
health care insurance or without a usual source of health care. Only a small percentage of 
respondents had ever had CT colonography [1.3% (95% CI, 1.0–1.7)]. Use of CT 
colonography was very low in all subgroups (Table 3).
The frequency of reported reasons for not having a CRC test was similar among respondents 
who had never had any kind of CRC test and those respondents who had a CRC test but not 
within the recommended time interval (Table 4). The most commonly reported reason for 
not having a CRC test was “no reason or never thought about it,” reported by about 40%. 
About 15% reported the reason for not having a CRC test as “doctor did not order it or did 
not say I needed it.” Other reasons reported by more than 10% of respondents were “Have 
not had any problems” or “Did not need it or did not know I needed this type of test.”
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While most of our analyses were among persons ages 50 to 75 years, we also examined the 
percentage of respondents ages 76 to 84 years who reported home FOBT use within the past 
year, sigmoidoscopy use within the past 5 years in combination with FOBT use within the 
past 3 years, or colonoscopy use within the past 10 years. The percentage of respondents 
ages 76 to 84 that reported use of any of these CRC tests within these time intervals was 
62.5% (95% CI, 59.4–65.5), very similar to the percentage for respondents ages 50 to 75 
years. The percentages that used each type of test within these time intervals were also very 
similar for ages 76 to 84 years (data not shown). For ages 76 to 84 years, the percentage that 
had never been screened for CRC with home FOBT, sigmoidoscopy, or colonoscopy was 
22.7% (95% CI, 20.2–25.3).
Discussion
According to the data from the NHIS, a national survey of the general population, an 
estimated 58.3% of the U.S. population ages 50 to 75 years met recommendations for CRC 
testing in 2010. Colonoscopy was, by far, the most commonly used CRC test, with an 
estimated 54.6% of respondents reporting use of this procedure within the past 10 years. 
Home FOBT was used by 8.8% of respondents within the past year. Sigmoidoscopy was 
infrequently used.
The estimated percentage of the U.S. population ages 50 to 75 years that has used CRC tests 
within recommended time intervals has increased since 2008, from approximately 54.5% 
(11, 18). Use of CRC tests has been increasing since 1992 (11, 18–20). Since 2000, this 
increase reflects an increased use of colonoscopy because use of FOBT and sigmoidoscopy 
has been steadily declining (11).
Compared with the 2010 NHIS, results from the state-based 2010 Behavioral Rick Factor 
Surveillance System (BRFSS) survey showed that a slightly higher proportion (65.4%) of 
the U.S. population ages 50 to 75 years had reported CRC testing within recommended time 
intervals (21). Differences in the results from the 2 surveys may have been due to the 
different modes of administration and different response rates for the 2 surveys. The BRFSS 
is a telephone survey and has a lower response rate than the NHIS. BRFSS rates were also 
higher than NHIS rates in earlier years, both for CRC testing and mammography (12, 22–
24).
The factors that we found to be associated with CRC testing among respondents ages 50 to 
75 years in the 2010 NHIS were similar to the factors associated with CRC testing in earlier 
NHIS surveys (11, 12, 22). Sociodemographic factors, such as age, education, and income, 
and factors related to health care access, such as type of health care insurance and having a 
usual source of health care, were associated with CRC test use. The proportion that had a 
CRC test within the recommended time interval was particularly high for respondents who 
had military health care insurance. Use of CRC screening tests may be high in those with 
military health care insurance because the Veterans Health Administration has established 
performance measures for CRC screening, uses electronic clinical reminders for CRC 
screening, and initiated a CRC screening and diagnosis quality improvement effort in 2005 
Shapiro et al. Page 7
Cancer Epidemiol Biomarkers Prev. Author manuscript; available in PMC 2015 July 02.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
(25). In addition, a Veterans Health Administration directive on CRC screening in January 
2007 mandated that each eligible veteran must be offered CRC screening (26).
Use of CRC tests was also high for respondents with private health care insurance, with high 
family income, for college graduates, and for respondents ages 60 to 75 years. Use of CRC 
tests was particularly low for respondents without health care insurance and those without a 
usual source of health care. The great majority of respondents without health care insurance 
were younger than 65 years, due to Medicare coverage for those ages 65 years and older. 
Changes in health care coverage may be particularly important for increasing CRC 
screening.
The most common reason for nonuse among respondents who had not had a CRC test within 
the recommended time period was “no reason or never thought about it.” This has not 
changed since 2000, the first time a question on the reason for nonuse of CRC tests was 
included on the NHIS (22). These results highlight the continued need to educate the public 
and health care professionals about the importance of CRC screening.
A newer type of CRC test is CT colonography, which is not recommended by the USPSTF 
due to insufficient evidence to support its use in population screening (1). However, it has 
been recommended by other national organizations (8). Questions about awareness and use 
of CT colonography were included on the NHIS for the first time in 2010. Awareness of this 
test appears to be quite low; only about a fifth of respondents reported that they had heard of 
CT colonography or virtual colonoscopy. Whites, non-Hispanics, college graduates, and 
respondents with private health care insurance or a usual source of health care were more 
likely to have heard of CT colonography. Results from the 2010 NHIS indicated that CT 
colonography was infrequently used in all subgroups, with only 1.3% overall ever having 
had this type of test. Infrequent use of CT colonography is likely due to the fact that 
Medicare and other national health care plans do not currently pay for this test for CRC 
screening.
Office FOBT was reported by 5.3% of respondents, even though it is not considered an 
acceptable CRC screening test (1, 8) because of very poor sensitivity (27). Only home 
FOBT has been shown to reduce CRC mortality in randomized controlled trials (2, 3, 7). 
Since 2002, national screening guidelines have explicitly recommended against use of office 
FOBT (1, 8, 28, 29). Medicare has not reimbursed for CRC screening with office FOBT 
since 2007 (30). Despite efforts to stop use of office FOBT, many physicians continue to 
perform it (31). Although the percentage of adults reporting office FOBT in 2010 was lower 
than in the 2000 NHIS (32), use of office FOBT was still at an unacceptable level for such a 
poor test and efforts to stop its use should continue.
For the first time in 2008, the USPSTF recommended an age to stop CRC screening (1). 
Results of a decision analysis using microsimulation models indicated that continuing 
screening after the age of 75 years for those individuals who have had regular, negative 
screenings would add little benefit (33, 34). The decision analysis that contributed to this 
recommendation was based on chronologic age, but the recommendations acknowledge that, 
in practice, the decision to stop screening should also consider the health of the patient (1, 
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33, 34). Our results from the 2010 NHIS indicated that 23% of respondents ages 76 to 84 
years had never been screened and should possibly be considered for screening, taking into 
account their health care status. Because the USPSTF recommendations for an age to stop 
screening are relatively recent, use of CRC screening in older persons may decrease in the 
future if this recommendation is followed, although other organizations have not specified 
an age to stop screening (8).
There are several limitations to this analysis. Some respondents may have incorrectly 
reported their use of CRC tests. However, studies comparing self-report of CRC test use 
with information from medical records have generally found moderate-to-good agreement 
between the 2 data sources (35–39). In addition, the response rate for the survey was only 
60.8% and respondents may have differed from nonrespondents in use of CRC tests.
In conclusion, data from the 2010 NHIS show that there has been some progress in use of 
CRC testing in the last few years. However, approximately 40% of the U.S. population ages 
50 to 75 years have not had a CRC test within recommended time intervals. CT 
colonography appears to be little known and infrequently used. Use of CRC screening tests 
is particularly low in certain population subgroups, especially those without a usual source 
of health care and without health care insurance. Expansion of health care coverage to more 
of the U.S. population may increase use of CRC screening tests and thereby accelerate the 
decline in CRC mortality (21, 40). Moreover, as our results indicate that many people are 
still not aware of the need for CRC screening, the active engagement of public health and 
health care professionals in educating the public and talking to patients is needed to increase 
awareness of the importance of screening for this often preventable disease.
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Table 3
Awareness and use of CT colonography among respondents ages 50 to 75 years, by sociodemographic and 
health care access variables, National Health Interview Survey (NHIS), 2010
Characteristic
Heard of CT colonography Ever had CT colonography
Na %b (95% CI) Na %b (95% CI)
Total 8,848 20.3 (19.2–21.4) 8,843 1.3 (1.0–1.7)
Gender
 Male 3,891 19.8 (18.2–21.5) 3,888 1.7 (1.2–2.4)
 Female 4,957 20.8 (19.4–22.2) 4,955 1.0 (0.7–1.3)
Race
 White 6,756 21.7 (20.4–23.0) 6,751 1.3 (1.0–1.7)
 Black 1,517 12.8 (11.1–14.8) 1,517 1.8 (1.2–2.7)
 Asian 470 12.9 (9.6–17.2) 470 0.4 (0.1–1.6)
 American Indian/Alaska native 82 17.3 (9.9–28.6) 82 1.1 (0.2–5.7)
Hispanic or Latino
 No 7,676 21.4 (20.2–22.6) 7,672 1.3 (1.0–1.6)
 Yes 1,172 9.5 (7.7–11.7) 1,171 2.0 (1.1–3.7)
Age, y
 50–59 4,172 19.6 (18.0–21.2) 4,171 0.8 (0.5–1.3)
 60–69 3,348 22.3 (20.6–24.2) 3,347 2.0 (1.5–2.7)
 70–75 1,328 18.4 (16.0–21.1) 1,325 1.5 (0.9–2.4)
Education
 <12 y 1,523 9.5 (7.6–11.6) 1,521 1.4 (0.8–2.5)
 High school graduate 2,451 13.2 (11.7–14.9) 2,450 1.0 (0.7–1.7)
 Some college 2,490 22.3 (20.1–24.6) 2,488 1.2 (0.7–1.9)
 College graduate 2,351 31.0 (28.6–33.4) 2,351 1.6 (1.1–2.5)
Health care insurance-–ages 50–64
 Private 3,969 23.2 (21.5–24.9) 3,967 1.0 (0.7–1.5)
 Military without private 269 17.5 (12.4–24.1) 269 2.5 (1.2–5.2)
 Only government/public 826 12.4 (10.0–15.4) 826 2.0 (1.1–3.7)
 None/single service 975 13.4 (11.0–16.3) 975 0.3 (0.1–0.8)
Health care insurance-–ages 65—75
 Private 1,338 23.8 (21.1–26.8) 1,337 1.5 (0.9–2.5)
 Medicare without private 1,370 15.6 (13.5–18.0) 1,368 1.9 (1.2–3.0)
 Only government/public 40 10.8 (4.8–22.6) 40 3.2 (0.8–12.3)
 None/single service 42 2.8 (0.4–16.7) 42 0.0 (0.0–8.4)
Usual source of health care
 No 872 15.9 (12.9–19.4) 871 1.5 (0.7–2.9)
 Yes 7,975 20.7 (19.5–21.9) 7,971 1.3 (1.0–1.7)
aSample size for each response category.
b
Estimates are age-adjusted to the 2000 U.S. standard population using the following age groups: 50–54, 55–59, 60–64, 65–69, and 70–75.
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Table 4
Reasons for not having a CRC test, among respondents ages 50 to 75 years, National Health Interview Survey 
(NHIS), 2010
Most important reason for not having CRC 
test
For respondents who never had any kind 
of CRC test (N = 2,964)
For respondents who had a CRC test, but 
not within recommended time interval (N = 
3,749)
N % (95% CI) N % (95% CI)
No reason or never thought about it 1,281 41.0 (38.6–43.3) 1,548 39.5 (37.4–41.6)
Doctor did not order it or did not say I needed 
it
435 14.9 (13.3–16.7) 578 15.1 (13.7–16.7)
Have not had any problems 388 13.6 (12.1–15.1) 509 14.2 (12.9–15.6)
Did not need it or did not know I needed this 
type of test
329 12.1 (10.7–13.8) 403 11.7 (10.4–13.2)
Too expensive or no insurance or cost 174 5.4 (4.5–6.4) 228 5.8 (5.0–6.8)
Put it off or did not get around to it 121 4.6 (3.8–5.7) 172 5.1 (4.4–6.0)
Do not have doctor 99 3.4 (2.7–4.3) 110 3.0 (2.4–3.7)
Too painful, unpleasant, or embarrassing 57 2.0 (1.4–2.8) 79 2.1 (1.6–2.8)
Had another type of colorectal examination 4 0.1 (0.0–0.4) 5 0.1 (0.0–0.3)
Other 76 2.8 (2.1–3.7) 117 3.3 (2.7–4.1)
NOTE: This question was asked of respondents who had not had a colonoscopy in the past 10 years, sigmoidoscopy in the past 5 years, CT 
colonography in the past 5 years, or FOBT in the past year.
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